Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
4.36%
Grew
—
—
Shrank
—
1 Year
Score—
Net Growth4.36%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
—
13.05%
40%
—
—
Never
—
5 Years
Score—
Net Growth13.05%
Net Trend40%
Net Income Consistency—
Rev Growth—
Rev TrendNever
Revenue Consistency—
Explore the 2021 public Archive ranking →
Where Cellectar Biosciences Inc has ranked, year by year
Measure
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- CLRB
2011: 64.9% · 2013: 69.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 1.84 | — |
1 Year2025-09-30 | $ 5.60 | -67.14% |
5 Years2021-09-30 | $ 277.50 | -99.34% |
10 Years2016-09-30 | $ 8.13K | -99.98% |
20 Years2006-09-29 | $ 1000K | -100.00% |
All Time2005-11-10 | $ 1000K | -100.00% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | All Time2005-11-10 |
|---|---|---|---|---|---|---|
| Price | $ 1.84 | $ 5.60 | $ 277.50 | $ 8.13K | $ 1000K | $ 1000K |
| Return | — | -67.14% | -99.34% | -99.98% | -100.00% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 20M | $ 8M |
| 2025 | $ 0.00 | -$ 21M | $ 13M |
| 2024 | $ 0.00 | -$ 44M | $ 23M |
| 2023 | $ 0.00 | -$ 42M | $ 9M |
| 2022 | $ 0.00 | -$ 28M | $ 19M |
| 2021 | $ 0.00 | -$ 23M | $ 35M |
| 2020 | $ 0.00 | -$ 15M | $ 57M |
| 2019 | $ 0.00 | -$ 14M | $ 10M |
| 2018 | $ 0.00 | -$ 13M | $ 13M |
| 2017 | $ 0.00 | -$ 13M | $ 10M |
| 2016 | $ 0.00 | -$ 6M | $ 11M |
| 2015 | $ 0.00 | -$ 5M | $ 3M |
| 2014 | $ 0.00 | -$ 8M | $ 9M |
| 2013 | $ 0.00 | -$ 10M | $ 2M |
| 2012 | $ 0.00 | -$ 8M | $ 4M |
| 2011 | -$ 11K | -$ 7M | $ 5M |
| 2010 | $ 33.33K | $ 2M | $ 2M |
| 2009 | $ 96.31K | -$ 22M | $ 8M |
| 2008 | $ 125.97K | -$ 16M | $ 1M |
| 2007 | -$ 19M | $ 9M | |
| 2006 | $ 12.58K | -$ 8M | $ 9M |
| IPO2005 | $ 12.58K | -$ 3M | $ 4M |
Cellectar Biosciences Inc fundamental performance
Between 2005 and 2025, revenue declined from $ 12.58K to $ 0.00 and net income went from -$ 3M to -$ 21M. Revenue increased in 1 of those 20 years; net income in 7.
Cellectar Biosciences Inc currently holds a 20-year HDB Score of 1.3 out of 10. How the HDB Score is calculated.
Membership
Continue CLRB’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
